These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33275745)

  • 21. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
    Platzbecker U; Hofbauer LC; Ehninger G; Hölig K
    Leuk Res; 2012 May; 36(5):525-36. PubMed ID: 22300879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Retrospective analysis of hemotherapy support in 226 cases of myelodysplastic syndromes].
    Rubio-Félix D; Franco E; Giraldo P; Gimeno J; Cuesta I; Giralt M
    Sangre (Barc); 1994 Apr; 39(2):117-20. PubMed ID: 8059289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The epidemiology of platelet transfusions: an analysis of platelet use at 12 US hospitals.
    Gottschall J; Wu Y; Triulzi D; Kleinman S; Strauss R; Zimrin AB; McClure C; Tan S; Bialkowski W; Murphy E; Ness P;
    Transfusion; 2020 Jan; 60(1):46-53. PubMed ID: 31850522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.
    Garcia-Manero G; Almeida A; Giagounidis A; Platzbecker U; Garcia R; Voso MT; Larsen SR; Valcarcel D; Silverman LR; Skikne B; Santini V
    BMC Hematol; 2016; 16():12. PubMed ID: 27148452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies for achieving transfusion independence in myelodysplastic syndromes.
    Thomas ML
    Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of blood product use among patients with myelodysplastic syndrome.
    Ramsey SD; McCune JS; Blough DK; McDermott CL; Beck SJ; López JA; Deeg HJ
    Vox Sang; 2012 May; 102(4):331-7. PubMed ID: 22115321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.
    Castelli R; Schiavon R; Deliliers GL
    Med Oncol; 2018 Feb; 35(3):33. PubMed ID: 29417235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
    Almeida A; Fenaux P; List AF; Raza A; Platzbecker U; Santini V
    Leuk Res; 2017 Jan; 52():50-57. PubMed ID: 27883945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes.
    DeZern AE; Binder G; Rizvi S; Corvino FA; Arikian SR; Surinach A; Lee J; Smith BD
    Leuk Lymphoma; 2017 Nov; 58(11):2649-2656. PubMed ID: 28482722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population-based study.
    Rozema J; van Roon EN; Kibbelaar RE; Veeger NJGM; Slim CL; de Wit H; Hoogendoorn M;
    Transfusion; 2021 Oct; 61(10):2877-2884. PubMed ID: 34480360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse impact of hyperferritinemia and transfusion dependency on treatment success in myelodysplastic syndrome.
    Cakar MK; Yegin ZA; Baysal NA; Altındal S; Pamukçuoğlu M; Celik B; Yenicesu I
    Transfus Apher Sci; 2013 Jun; 48(3):397-401. PubMed ID: 23619324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Transfusions in myelodysplastic syndromes].
    Rose C
    Transfus Clin Biol; 2017 Sep; 24(3):209-215. PubMed ID: 28651884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey.
    Cornelissen LL; Caram-Deelder C; Meier RT; Zwaginga JJ; Evers D;
    Eur J Haematol; 2021 Mar; 106(3):362-370. PubMed ID: 33226659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned.
    Oliva EN; Platzbecker U; Fenaux P; Garcia-Manero G; LeBlanc TW; Patel BJ; Kubasch AS; Sekeres MA
    Blood Rev; 2021 Nov; 50():100851. PubMed ID: 34088518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes.
    Jansen AJ; Essink-Bot ML; Beckers EA; Hop WC; Schipperus MR; Van Rhenen DJ
    Br J Haematol; 2003 Apr; 121(2):270-4. PubMed ID: 12694248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of Transfusion Therapy Effectiveness in Patients with Myelodysplastic Syndrome].
    Yin ZH; Pang ZR; Fang XC; Kong XJ; Yan C; He JJ; Xu J; Chen S; Zhu F; Chen Y; Tan QX; Gui L; Shi JN; Zhang HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1648-1653. PubMed ID: 33067968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials.
    Mo A; McQuilten ZK; Wood EM; Weinkove R
    Intern Med J; 2017 Jun; 47(6):695-698. PubMed ID: 28580745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.